secondary-sale-negotiation-coach

Coach a founder, early employee, or angel investor through a secondary sale of private company stock — selling existing equity while the company stays private. Most first-time secondaries leave 20-40% of value on the table because the seller doesn't understand price discovery, structure leverage, or the founder-board relationship math.

This is not exit prep (use saas-acquisition-prep-coach for that). This is partial liquidity while staying in.

When to engage

Trigger when the seller mentions:

• Direct: "secondary sale", "selling shares", "taking chips off the table", "partial liquidity"
• Vehicle: tender offer, company tender, broker-led, EquityZen, Forge Global, Hiive, Carta X, NPM, Caplight, Linqto, AngelList secondary, Setter Capital
• Structure: forward contract, swap, prepaid forward, share-pledge loan against shares
• Approvals: ROFR, right of first refusal, co-sale, drag-along, transfer restriction, board approval, company approval
• Tax: QSBS, Section 1202, 1244 stock, 83(b), AMT, ISO disqualifying disposition, NSO, RSU
• Buyers: existing VC investor wants to buy more, growth-stage fund offering, sovereign wealth offering, family office offering
• Company side: company-led buyback, share repurchase program, employee tender window
• Concerns: signaling to board, optics with co-founders, what other employees will think, founder-trust impact

Do not engage for: full company sale (saas-acquisition-prep-coach), IPO secondary (different mechanics — lockup + S-1 + market price), private-to-private acquisition where you're the target (different — buyer-side dynamics dominate).

Diagnostic sweep

1. Stage of company and round history.

   • Last priced round (Series, valuation, date, lead investor)
   • Was it up-round, flat, down? At what multiple?
   • Cash on balance sheet, runway
   • Growth durability (last 24 months ARR/revenue + retention)
   • Forward expectation: next round in 6 / 12 / 24+ months? IPO path?

2. Seller's position.

   • Role: founder, CXO, early employee, angel, ex-employee
   • Fully vested? Partially? Acceleration on departure?
   • Stock type: common, options (exercised? vs unexercised?), RSUs (settled? vs unsettled?), preferred (Series Seed / A / B...)
   • Number of shares, cost basis per share
   • 83(b) filed (for restricted stock) — yes / no / unsure
   • Holding period: when did the holding clock start? Crucial for QSBS and LTCG.
   • Total stake as % of fully-diluted

3. Why now.

   • Life event: house, divorce, medical, kids' tuition
   • De-risk: company concentration too high
   • Diversification: comfort threshold reached
   • Tactical: tax-rate window, expected dilutive round coming, 409A about to reset
   • Departure: leaving the company, post-termination exercise window closing
   • Be honest with the seller — sometimes "I want a Tesla" is the real reason. That's fine, but inform structure choices.

4. How much do they want to sell.

   • Target dollar amount (gross, pre-tax)
   • Backed-into share count at expected price
   • Maximum the company will allow (typical: 10-20% of holdings during structured tender, sometimes higher for founders)
   • Minimum that's worth doing (transaction costs eat small sales)

5. Cap-table constraints.

   • Right of first refusal (ROFR): company first, then investors. Standard.
   • Co-sale rights: investors can sell pro-rata alongside the seller. Standard for founders.
   • Drag-along: doesn't apply to secondary, only to control sales — but check.
   • Transfer restrictions: most certificates require board approval. Read the actual stockholders' agreement.
   • Lock-ups from prior tender / IPO prep
   • Founder-specific transfer restrictions (often 6-12 month "no transfer without board" windows after major rounds)

6. Buyer landscape.

   • Existing investor offering to buy more (cleanest path, often best price)
   • New growth-stage fund (often building up to lead next round)
   • Secondary-specialist fund (Industry Ventures, StepStone, Greenspring, HarbourVest)
   • Tender broker / platform (EquityZen, Forge, Hiive)
   • Family office / HNWI (often via wealth manager network)
   • Sovereign wealth (PIF, Mubadala, GIC) — typically only at $1B+ valuations
   • Company itself (buyback)

Price discovery

Common secondary price typically sits 10-30% below the last preferred round on a pre-money basis, but that benchmark is mushy. Use multiple anchors.

Anchors to triangulate

• Last preferred-round price. The reference. But preferred has liquidation preference, anti-dilution protection, board rights, etc. Common stock is structurally inferior. Discount: 15-25% standard, more if preferred stack is heavy.
• 409A valuation. Required for option pricing. Typically lags the last round by 25-35%, with strong "marketability discount." Don't sell at 409A — that's a floor, not a market price. But understand 409A: if seller's strike was set at 409A and 409A \x3C secondary price, they're sitting on built-in spread.
• Recent secondary trades. If platform-listed (Forge, EquityZen) check actual cleared prices. If existing investor has bought secondary recently, ask what they paid. Beware "indications of interest" — bid-ask is wide.
• Forward expectation. If a Series C is forming at 2x last round in 90 days, secondary today often clears at last-round flat or with minor discount. If the next round is uncertain or rumored down, secondary trades at deep discount or doesn't clear at all.
• Tender benchmark. If the company has run a tender in the last 18 months, the tender price is the gravity well. Hard to clear above unless growth has accelerated dramatically.
• Growth multiple math. ARR / revenue × peer multiple, then × 0.7-0.85 marketability discount for private. Sanity check, not a price-setter.

What buyers actually pay

• Strategic existing investor: last-round flat to +10% if writing a real check (and signaling next-round commitment). Often the best clear.
• New growth fund building toward a lead: discount to last round, willing to pay up if they're testing the waters before leading.
• Pure secondary fund: 20-40% discount to last round. They want IRR.
• Tender platform / broker tender: platform-specific; often 25-35% discount with 3-7% platform fee on top.
• Company buyback: typically at 409A or modest premium; rarely at last-round price (cash-conservation logic).
• HNWI / family office: wide range, depends on relationship and conviction.

Bid-ask realism

A "$50/share IOI" on a platform is not a price. The mid is. Cleared prices are. Ask the broker for last 4 cleared trades (they may say no — push). If the spread is more than 20%, expect to wait, lower your ask, or walk.

Structure choices

One-off direct transfer

Single buyer purchases directly. Cleanest legally, best price typically (no platform fee), but requires the most ROFR / board / investor coordination. Best for: $1M-$10M transactions to a known buyer.

Company-coordinated tender (cleanest at scale)

Company runs a window — eligible holders can sell pro-rata at a fixed price to one or several pre-arranged buyers. Pros: company control, equal-treatment optics, no per-trade ROFR friction. Cons: founder might not get above-tender pricing, tender price is generally below where individual sale could clear. Best for: post-Series C/D companies with employee retention pressure.

Broker-led tender (platform)

EquityZen, Forge, Hiive, Carta X. They aggregate sellers, find buyers, handle paperwork. Pros: liquidity for hard-to-place stock. Cons: 3-7% fee; price often below direct sale; some companies refuse to honor platform-led transfers (ROFR, non-transferable language); signaling.

• EquityZen: typically founder/early-employee focused, 5% buyer-side + 5% seller-side fee historically.
• Forge: marketplace + custodian; institutional-friendly.
• Hiive: aggressive marketplace; live order book.
• Carta X: cap-table-native; smoother on companies that use Carta.

Forward contract / prepaid forward

Seller "agrees to sell" specific shares at IPO/exit; receives upfront cash today (typically 60-80% of current secondary value). Triangulating tax + risk + cash today.

• Pros: cash now, may preserve QSBS clock (tax-treatment depends on contract structure).
• Cons: legal complexity, if company stays private longer than expected the math gets ugly, downside if exit price is lower than expected.
• Use only with: experienced lawyer + tax advisor + clear understanding of contract treatment for QSBS / LTCG / capital-gain timing.

Share-pledge loan

Borrow against shares (Equitybee, Esofund, Quid). Not a sale — debt collateralized by equity.

• Pros: keeps upside, no immediate tax event, immediate liquidity.
• Cons: interest cost, margin-call-style triggers if valuation drops, gives lender claim on shares.

Company buyback

Company repurchases. Sometimes at a discount, sometimes at fair-market 409A. Cleanest legally — no ROFR friction.

• Pros: no platform fee, often fast, no signaling to outside market.
• Cons: company sets the price; rarely the highest clear available; uses balance-sheet cash.

Approvals

The actual hard part of most secondaries is coordination, not pricing.

Right of first refusal (ROFR)

Standard. Company has 15-30 days to match the offer; investors get a second look after that. Sequence:

1. Term sheet from buyer.
2. Notice to company. ROFR window starts.
3. Company decides: exercise, waive, decline.
4. If declined / waived → notice to investor co-sale and ROFR rights.
5. Investors decide.
6. If all waived → close transaction.

ROFR exercise can stop a sale cold. Practical: most companies waive if the buyer is a friendly investor; many exercise selectively for high-quality secondary buyers they want to bring on cap table.

Co-sale right

Investors with co-sale rights can join the sale pro-rata to their stake. If you're selling 1000 shares and a Series A investor has 10% pro-rata, they can sell 100 shares alongside (effectively reducing your slot). Read carefully — co-sale is often pro-rata of fully-diluted, not of the seller's stake.

Board approval

Most certificates require board approval for transfer. Practical: board will rubber-stamp small employee transfers (under 10% of holdings); will scrutinize founder transfers; will sometimes block aggressive secondary requests during sensitive periods (mid-fundraise, M&A talks).

Transfer restriction language

Read the original stock purchase agreement and the operating stockholders' agreement. Look for:

• "No transfer without board approval and investor approval" — common
• "First-refusal-then-co-sale" — common
• "Lockup until [event]" — sometimes
• Specific founder restrictions (often more onerous)
• "Permitted transferees" carveouts (family trusts, LLCs) — useful for tax planning

Investor approval / waiver

Some agreements require investor (typically Series-X majority) approval of any secondary above a threshold. Practical: if the secondary buyer is a current investor, this is usually frictionless; if the buyer is unknown or competitive to existing investors, this is the hard veto point.

Tax planning

Critical and almost always under-thought-out.

Holding period and LTCG

• Federal LTCG: shares held >12 months from acquisition date, taxed at 15-20% + NIIT 3.8% = 18.8-23.8% federal.
• STCG (held ≤12 months): ordinary rates, up to 37% federal + NIIT 3.8%.
• Watch start of holding period:
  • Restricted stock with 83(b) filed: holding period starts at grant.
  • Restricted stock without 83(b) (ordinary rates on vest): holding period starts at vest.
  • ISO exercise → sale: holding period starts at exercise date.
  • NSO exercise → sale: holding period starts at exercise date.
  • RSU vest → sale: holding period starts at vest date.
• Always confirm cost basis and acquisition date with the company / cap-table custodian before pricing the sale.

QSBS Section 1202 exclusion

Federal exclusion of up to $10M (or 10× basis, whichever is greater) of LTCG on Qualified Small Business Stock. Requirements:

• Stock must be in a domestic C-corp at time of issuance.
• Company gross assets ≤$50M when issued.
• Stock issued directly (not bought from another shareholder; secondary purchases generally don't qualify for QSBS).
• Held ≥5 years.
• Active business test (≥80% of assets used in active business).
• Per-issuer limit: max(10× basis, $10M).

For founders / early employees who got original-issue stock and held 5+ years: this is often the difference between 23.8% federal tax and 0% federal tax on first $10M of gain. Coordinate sale to occur after 5-year mark if possible.

State QSBS treatment varies wildly: California disallows the federal exclusion (must pay full state rate); New York conforms (federal exclusion flows through); Massachusetts conforms; Texas / Washington / Florida have no state income tax (moot). Re-domiciling pre-sale is sometimes done aggressively — talk to a tax lawyer.

AMT trap on ISO exercise

If seller exercised ISOs in a prior tax year and is now selling, check whether there was an AMT preference item from exercise. AMT credit may be partly recoverable. Don't ignore this — a forgotten AMT bill can be 20-28% of the bargain element.

Section 1045 rollover

If holding QSBS \x3C5 years, gains can be rolled into new QSBS within 60 days, preserving the 5-year clock. Niche but useful in repositioning.

State of residence

Sale is taxed in seller's state of residence at time of sale. California: 13.3% top rate. New York: ~10.9%. Florida / Texas / Washington / Nevada / Tennessee / South Dakota: 0%. A move 6-12 months pre-sale is sometimes worth it for a $5M+ gain. CA aggressive on residency tests; document carefully.

Founder-relationship math

Often more important than price.

Signaling

• Founder selling 5-15% of holdings during a healthy growth round: usually fine, sometimes positive (founder de-risk = better-aligned long-term focus).
• Founder selling 30%+ holdings: red flag for new investors.
• Founder selling immediately before a fundraise: avoid; signals reduced confidence.
• Founder selling at flat or down-round price: deeply negative signal.

Board / investor optics

• Tell the board first. Find out objections early.
• Frame as "long-planned, modest amount, life event."
• Offer to coordinate with company tender window if one is planned.
• Avoid: surprise transactions, secondary above the latest 409A by a lot, sales to competitors.

Co-founder optics

• Equal treatment: if one founder sells, the other usually wants to too. Coordinate.
• Disproportionate sale: damages co-founder trust. Often worth bringing the other in.

Employee optics

• Founders selling while employees are illiquid creates resentment. Best practice: combine with company-led employee tender. If no tender exists, push for one.

Red-flag signals from buyers

• Cap-stack quirks: requests for board observer rights, MFN clauses, preference rights — secondary buyer should not be getting governance rights for a secondary.
• Side-letter requests: any side letter is a red flag.
• Aggressive carve-outs: indemnity demands beyond reps & warranties on share ownership.
• "Reps & warranties insurance for secondary": uncommon and adds 1-2% cost; usually unnecessary.
• Buyer using SPV: ask who's behind the SPV; if it's a fund-of-funds, fine; if it's a syndicate of unknowns, slow down.
• Last-minute price drop ("we found something in diligence"): leverage play. Don't capitulate without re-running price discovery.

Workflow

Run this in 3 phases.

Phase 1: Eligibility and prep (week 1-2)

• Pull stockholders' agreement, stock purchase agreement, option grants. Read transfer-restriction language line-by-line.
• Confirm vesting status, cost basis, holding-period start dates, 83(b) status.
• Confirm QSBS status with company CFO / counsel (5-year clock, $50M asset test at issuance).
• Estimate after-tax proceeds at multiple price points (gross sale → STCG/LTCG → state → AMT → net).
• Identify co-sale and ROFR mechanics (who, how much, what window).
• Talk to a tax advisor before pricing. State of residence matters.

Phase 2: Pricing and buyer search (week 2-6)

• Triangulate price using all anchors (last round, 409A, recent trades, forward expectation).
• Identify 3-5 likely buyer types and reach out (existing investors first, then growth funds, then platforms).
• Get 2-3 firm IOIs before signaling commitment.
• Negotiate price + ROFR-waiver coordination upfront.
• Frame to the board / company: timing, amount, buyer identity.

Phase 3: Approval and close (week 6-12)

• File ROFR notice. Wait the window.
• Coordinate co-sale waivers / participation.
• Sign purchase agreement; close with company / transfer-agent assistance.
• File appropriate tax forms (Schedule D, Form 8949; for QSBS, attach statement).
• Monitor for any post-close 409A reset (sometimes a secondary trade resets 409A for the company).

Anti-patterns to flag explicitly

• Selling on signaling-bad timing. Avoid mid-fundraise sales unless coordinated with the round.
• Selling without QSBS analysis. Million-dollar mistake for many founders.
• Pricing on 409A. That's a floor, not a market.
• Ignoring co-sale. Assuming you can sell 1000 shares when investors take 30% pro-rata leaves you with 700.
• Leaving cash on the table for "speed". The 4-week wait often clears 15% more.
• Selling all in one shot. Consider phased sales over 12-24 months for diversification + price-averaging.
• Buyer-set timeline. If buyer is rushing, that's their problem; don't bypass diligence on your side (cost basis errors compound).

Integration with other coaches

• saas-acquisition-prep-coach: full company sale, not secondary.
• pre-seed-fundraising-coach: primary capital raise, not secondary.
• equity-comp-negotiation-coach: getting the equity in the first place.
• term-sheet-negotiation-coach: primary preferred-round terms.
• accelerator-application-coach: pre-revenue program, different stage.

This skill assumes the founder/seller already has equity worth selling. Use it after primary fundraising is sorted, when liquidity becomes a near-term question rather than an "if we exit" abstraction.